Quarterly Updates6 Nov 2025, 07:02 pm
Alivus Life Sciences Reports 16% YoY Revenue Growth in Q2FY26, EBITDA Margins at 33.0%
AI Summary
Alivus Life Sciences Limited, a leading developer and manufacturer of high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs), announced its financial results for the quarter and half year ended September 30, 2025. The company reported a Revenue from operations of Rs. 5,880 Mn for Q2FY26, a growth of 16.0% YoY. EBITDA for Q2FY26 was at Rs. 1,939 Mn, a growth of 35.7% YoY with EBITDA margins at 33.0%, up 480 bps YoY. PAT for Q2FY26 stood at Rs. 1,301 Mn, a growth of 36.5% YoY and PAT margins were at 22.1%, up 330 bps YoY. The company also generated a strong free cash flow of Rs. 1,477 Mn in H1FY26.
Key Highlights
- Revenue from operations grew by 16.0% YoY in Q2FY26
- EBITDA margins increased by 480 bps YoY in Q2FY26
- PAT grew by 36.5% YoY and PAT margins increased by 330 bps YoY in Q2FY26
- The company generated a strong free cash flow of Rs. 1,477 Mn in H1FY26
- The company remains confident of maintaining margins at around 30% and delivering a stronger performance in the second half